Summary of findings 1. Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache.

Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache
Patient or population: adults with migraine headache ‐ moderate or severe and mild baseline pain Settings: community Intervention: sumatriptan 50 mg or 85 mg plus naproxen 500 mg Comparison: placebo
Outcomes	Probable outcome with comparator	Probable outcome with intervention	NNT or NNH (95% CI)	No. of studies, attacks, events	Quality of the evidence (GRADE)	Comments
Pain‐free response at 2 h for moderate to severe baseline pain	77 in 1000	280 in 1000	RR 3.7 (2.8 to 4.5) NNT 4.9 (4.3 to 5.7)	4 studies, 2596 attacks, 462 events	High	Adequate numbers of studies and attacks, study quality good, consistency of response
Pain‐free response at 2 h for mild baseline pain	180 in 1000	500 in 1000	RR 2.8 (2.4 to 3.1) NNT 3.1 (2.9 to 3.5)	8 studies, 3395 attacks, 1252 events	High	Adequate numbers of studies and attacks, study quality good, consistency of response
Headache relief at 2 h for moderate to severe baseline pain	270 in 1000	580 in 1000	RR 2.2 (2.0 to 2.4) NNT 3.2 (2.9 to 3.6)	4 studies, 2596 attacks, 1107 events	High	Adequate numbers of studies and attacks, study quality good, consistency of response
Sustained pain‐free during the 24 h post dose for moderate to severe baseline pain	60 in 1000	200 in 1000	RR 3.4 (2.7 to 4.4) NNT 7.9 (5.9 to 8.5)	4 studies, 2596 attacks, 339 events	Moderate	Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size and modest number of events
Sustained pain‐free during the 24 h post dose for mild baseline pain	120 in 1000	370 in 1000	RR 3.0 (2.6 to 3.6) NNT 4.1 (3.7 to 4.6)	8 studies, 3396 attacks, 907 events	High	Adequate numbers of studies and attacks, study quality good, consistency of response
Sustained headache relief during the 24 h post dose for moderate or severe baseline pain	160 in 1000	430 in 1000	RR 2.6 (2.3 to 3.0) (NNT 3.8 (3.4 to 4.3)	4 studies, 2596 attacks, 768 events	High	Adequate numbers of studies and attacks, study quality good, consistency of response
At least 1 AE during treatment for moderate to severe baseline pain	120 in 1000	210 in 1000	RR 2.0 (1.6 to 2.4) NNH 11 (8.3 to 15)	4 studies, 2793 attacks, 465 events	Moderate	Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size
At least 1 AE during treatment for mild baseline pain	82 in 1000	140 in 1000	RR 1.5 (1.2 to 1.9) NNH 18 (13 to 30)	6 studies, 2823 attacks, 329 events	Moderate	Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size and modest number of events
Serious AE (all levels of baseline pain)	No events	1 event possibly related to intervention	‐	‐	‐	‐
AE: adverse event; CI: confidence interval; NNT: number needed to treat for an additional beneficial outcome; NNH: number needed to treat for an additional harmful outcome; RR: risk ratio.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.